Booster or additional vaccination doses in patients vaccinated against COVID-19.
Saved in:
| Title: | Booster or additional vaccination doses in patients vaccinated against COVID-19. |
|---|---|
| Alternate Title: | Dosis vacunales de recuerdo o adicionales en pacientes vacunados frente a COVID-19. |
| Authors: | García-Botella, Alejandra1, García-Lledó, Alberto2, Gómez-Pavón, Javier3, González del Castillo, Juan4, Hernández-Sampelayo, Teresa5, Cruz Martín-Delgado, Mari6, Martín Sánchez, Francisco Javier7, Martínez-Sellés, Manuel8, Molero García, José María9, Moreno Guillén, Santiago10, Rodríguez-Artalejo, Fernando11, Ruiz-Galiana, Julián12, Cantón, Rafael13, De Lucas Ramos, Pilar14, Bouza, Emilio15 |
| Source: | Revista Española de Quimioterapia. abr2022, Vol. 35 Issue 2, p105-114. 10p. |
| Subjects: | BOOSTER vaccines, COVID-19, COVID-19 vaccines, PHYSICIANS, RNA regulation |
| Abstract (English): | Several health organizations, mainly in Western countries, have recently authorized the use of a booster dose of the COVID-19 vaccine for patients previously vaccinated with mRNA vaccines, with criteria that do not always coincide. The COVID Scientific Committee of the Illustrious College of Physicians of Madrid (ICOMEM) has received and asked several questions about this situation, to which the group has tried to give answers, after deliberation and consensus. The efficacy of the vaccines administered so far is beyond doubt and they have managed to reduce, fundamentally, the severe forms of the disease. The duration of this protection is not well known, is different in different individuals and for different variants of the virus and is not easily predictable with laboratory tests. Data on the real impact of a supplementary or "booster" dose in the scientific literature are scarce for the moment and its application in large populations such as those in the state of Israel may be associated with a decrease in the risk of new and severe episodes in the short observation period available. We also lack sufficient data on the safety and potential adverse effects of these supplementary doses and we do not know the ideal time to administer them in different situations. In this state of affairs, it seems prudent to administer supplemental doses to those exposed to a higher risk, such as immunocompromised individuals and the elderly. On the other hand, we consider that this is not the time to accelerate, on the spur of the moment, a massive administration of a third dose to other population groups that are less exposed and at lower risk, without waiting for adequate scientific information, which will undoubtedly arrive gradually. We do not believe that this position is incompatible with the practical and ethical warnings made by the World Health Organization in this respect. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Varias organizaciones sanitarias, fundamentalmente de países occidentales, han autorizado recientemente el uso de una dosis de refuerzo de la vacuna frente al COVID-19 para pacientes previamente vacunados con vacunas mRNA, con criterios no siempre coincidentes. El Comité Científico de COVID, del Ilustre Colegio de Médicos de Madrid (ICOMEM) ha recibido y se ha formulado diversas preguntas sobre esta situación, a la que el grupo ha tratado de dar respuestas, tras deliberación y consenso. La eficacia de las vacunas administradas hasta el momento está fuera de toda duda y han logrado disminuir, fundamentalmente, las formas graves de enfermedad. La duración de esa protección no se conoce bien, es diferente en distintos individuos y para distintas variantes del virus y no es fácilmente predecible con pruebas de laboratorio. Los datos sobre el impacto real de una dosis complementaria o "booster" en la literatura científica son escasos por el momento y su aplicación en grandes poblaciones como las del estado de Israel pueden asociarse a una disminución del riesgo de nuevos episodios y episodios graves en el corto periodo de observación disponible. Carecemos también de datos suficientes sobre la seguridad y potenciales efectos adversos de estas dosis complementarias e ignoramos el momento idóneo de administrarlas en distintas situaciones. En este estado de cosas, parece prudente administrar dosis complementarias a aquellos expuestos a un mayor riesgo, como pueden ser los individuos inmunodeprimidos y las personas mayores. Por el contrario, consideramos que no es este el momento de acelerar improvisadamente una administración masiva de una tercera dosis a otros grupos de población menos expuesta y de menor riesgo, sin esperar la adecuada información científica, que sin duda irá llegando paulatinamente. No creemos que esta posición, sea incompatible con las advertencias prácticas y éticas que realiza la Organización Mundial de la Salud a este respecto. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 155879763 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Booster or additional vaccination doses in patients vaccinated against COVID-19. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Dosis vacunales de recuerdo o adicionales en pacientes vacunados frente a COVID-19. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22García-Botella%2C+Alejandra%22">García-Botella, Alejandra</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22García-Lledó%2C+Alberto%22">García-Lledó, Alberto</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Gómez-Pavón%2C+Javier%22">Gómez-Pavón, Javier</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22González+del+Castillo%2C+Juan%22">González del Castillo, Juan</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Hernández-Sampelayo%2C+Teresa%22">Hernández-Sampelayo, Teresa</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Cruz+Martín-Delgado%2C+Mari%22">Cruz Martín-Delgado, Mari</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Martín+Sánchez%2C+Francisco+Javier%22">Martín Sánchez, Francisco Javier</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Martínez-Sellés%2C+Manuel%22">Martínez-Sellés, Manuel</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Molero+García%2C+José+María%22">Molero García, José María</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Moreno+Guillén%2C+Santiago%22">Moreno Guillén, Santiago</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Rodríguez-Artalejo%2C+Fernando%22">Rodríguez-Artalejo, Fernando</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Ruiz-Galiana%2C+Julián%22">Ruiz-Galiana, Julián</searchLink><relatesTo>12</relatesTo><br /><searchLink fieldCode="AR" term="%22Cantón%2C+Rafael%22">Cantón, Rafael</searchLink><relatesTo>13</relatesTo><br /><searchLink fieldCode="AR" term="%22De+Lucas+Ramos%2C+Pilar%22">De Lucas Ramos, Pilar</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22Bouza%2C+Emilio%22">Bouza, Emilio</searchLink><relatesTo>15</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Española+de+Quimioterapia%22">Revista Española de Quimioterapia</searchLink>. abr2022, Vol. 35 Issue 2, p105-114. 10p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22BOOSTER+vaccines%22">BOOSTER vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19+vaccines%22">COVID-19 vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22PHYSICIANS%22">PHYSICIANS</searchLink><br /><searchLink fieldCode="DE" term="%22RNA+regulation%22">RNA regulation</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Several health organizations, mainly in Western countries, have recently authorized the use of a booster dose of the COVID-19 vaccine for patients previously vaccinated with mRNA vaccines, with criteria that do not always coincide. The COVID Scientific Committee of the Illustrious College of Physicians of Madrid (ICOMEM) has received and asked several questions about this situation, to which the group has tried to give answers, after deliberation and consensus. The efficacy of the vaccines administered so far is beyond doubt and they have managed to reduce, fundamentally, the severe forms of the disease. The duration of this protection is not well known, is different in different individuals and for different variants of the virus and is not easily predictable with laboratory tests. Data on the real impact of a supplementary or "booster" dose in the scientific literature are scarce for the moment and its application in large populations such as those in the state of Israel may be associated with a decrease in the risk of new and severe episodes in the short observation period available. We also lack sufficient data on the safety and potential adverse effects of these supplementary doses and we do not know the ideal time to administer them in different situations. In this state of affairs, it seems prudent to administer supplemental doses to those exposed to a higher risk, such as immunocompromised individuals and the elderly. On the other hand, we consider that this is not the time to accelerate, on the spur of the moment, a massive administration of a third dose to other population groups that are less exposed and at lower risk, without waiting for adequate scientific information, which will undoubtedly arrive gradually. We do not believe that this position is incompatible with the practical and ethical warnings made by the World Health Organization in this respect. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Varias organizaciones sanitarias, fundamentalmente de países occidentales, han autorizado recientemente el uso de una dosis de refuerzo de la vacuna frente al COVID-19 para pacientes previamente vacunados con vacunas mRNA, con criterios no siempre coincidentes. El Comité Científico de COVID, del Ilustre Colegio de Médicos de Madrid (ICOMEM) ha recibido y se ha formulado diversas preguntas sobre esta situación, a la que el grupo ha tratado de dar respuestas, tras deliberación y consenso. La eficacia de las vacunas administradas hasta el momento está fuera de toda duda y han logrado disminuir, fundamentalmente, las formas graves de enfermedad. La duración de esa protección no se conoce bien, es diferente en distintos individuos y para distintas variantes del virus y no es fácilmente predecible con pruebas de laboratorio. Los datos sobre el impacto real de una dosis complementaria o "booster" en la literatura científica son escasos por el momento y su aplicación en grandes poblaciones como las del estado de Israel pueden asociarse a una disminución del riesgo de nuevos episodios y episodios graves en el corto periodo de observación disponible. Carecemos también de datos suficientes sobre la seguridad y potenciales efectos adversos de estas dosis complementarias e ignoramos el momento idóneo de administrarlas en distintas situaciones. En este estado de cosas, parece prudente administrar dosis complementarias a aquellos expuestos a un mayor riesgo, como pueden ser los individuos inmunodeprimidos y las personas mayores. Por el contrario, consideramos que no es este el momento de acelerar improvisadamente una administración masiva de una tercera dosis a otros grupos de población menos expuesta y de menor riesgo, sin esperar la adecuada información científica, que sin duda irá llegando paulatinamente. No creemos que esta posición, sea incompatible con las advertencias prácticas y éticas que realiza la Organización Mundial de la Salud a este respecto. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=155879763 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.37201/req/149.2021 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 10 StartPage: 105 Subjects: – SubjectFull: BOOSTER vaccines Type: general – SubjectFull: COVID-19 Type: general – SubjectFull: COVID-19 vaccines Type: general – SubjectFull: PHYSICIANS Type: general – SubjectFull: RNA regulation Type: general Titles: – TitleFull: Booster or additional vaccination doses in patients vaccinated against COVID-19. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: García-Botella, Alejandra – PersonEntity: Name: NameFull: García-Lledó, Alberto – PersonEntity: Name: NameFull: Gómez-Pavón, Javier – PersonEntity: Name: NameFull: González del Castillo, Juan – PersonEntity: Name: NameFull: Hernández-Sampelayo, Teresa – PersonEntity: Name: NameFull: Cruz Martín-Delgado, Mari – PersonEntity: Name: NameFull: Martín Sánchez, Francisco Javier – PersonEntity: Name: NameFull: Martínez-Sellés, Manuel – PersonEntity: Name: NameFull: Molero García, José María – PersonEntity: Name: NameFull: Moreno Guillén, Santiago – PersonEntity: Name: NameFull: Rodríguez-Artalejo, Fernando – PersonEntity: Name: NameFull: Ruiz-Galiana, Julián – PersonEntity: Name: NameFull: Cantón, Rafael – PersonEntity: Name: NameFull: De Lucas Ramos, Pilar – PersonEntity: Name: NameFull: Bouza, Emilio IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: abr2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 02143429 Numbering: – Type: volume Value: 35 – Type: issue Value: 2 Titles: – TitleFull: Revista Española de Quimioterapia Type: main |
| ResultId | 1 |
